相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas
Cheng Shen et al.
ANNALS OF MEDICINE (2022)
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial
Qiao-Qiao Shao et al.
HELICOBACTER (2022)
Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial
Jia-Lun Guan et al.
PHARMACOTHERAPY (2022)
Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study
Yi Hu et al.
HELICOBACTER (2022)
Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial
Bader Faiyaz Zuberi et al.
PAKISTAN JOURNAL OF MEDICAL SCIENCES (2022)
Effect of Helicobacter Pylori Eradication on Human Gastric Microbiota: A Systematic Review and Meta-Analysis
Yang Guo et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication
Yi Hu et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
Min Niu et al.
FRONTIERS IN PHARMACOLOGY (2022)
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
William D. Chey et al.
GASTROENTEROLOGY (2022)
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Peter Malfertheiner et al.
GUT (2022)
Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study
Ying-Ying Han et al.
HELICOBACTER (2022)
Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis
Yaobin Ouyang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)
Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis
Jinnan Chen et al.
PATHOGENS (2022)
2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment
Liya Zhou et al.
CHINESE MEDICAL JOURNAL (2022)
Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial
Hanxin Bi et al.
CHINESE MEDICAL JOURNAL (2022)
Implementation of WeChat-based patient-doctor interaction in the management of Helicobacter pylori infection: A propensity score matching analysis
Bo Shen Lin et al.
JOURNAL OF DIGESTIVE DISEASES (2022)
Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition)
Song-Ze Ding et al.
GUT (2022)
The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication ofHelicobacter pyloriinfection
Jianwei Yun et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice
Dana M. Harris et al.
DIGESTIVE DISEASES AND SCIENCES (2021)
Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy
Hiroyuki Eto et al.
HELICOBACTER (2021)
Impact of Helicobacter pylori eradication on the gastric microbiome
Li-Qi Mao et al.
GUT PATHOGENS (2021)
PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis
Cailing Li et al.
HELICOBACTER (2021)
The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults
Ziying Yuan et al.
HELICOBACTER (2021)
10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis
Pei-Ying Zou et al.
HELICOBACTER (2021)
Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication
Toshiki Horii et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori
Takahisa Furuta et al.
DIGESTION (2020)
Recent progress in Helicobacter pylori treatment
Yi Hu et al.
CHINESE MEDICAL JOURNAL (2020)
Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial
Yi Zhang et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
Sho Suzuki et al.
GUT (2020)
Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer
Yang Guo et al.
GUT (2020)
Searching for an optimal therapy forH pylorieradication: High-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days
Alex Hwong-Ruey Leow et al.
HELICOBACTER (2020)
Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis
Qunqun Ye et al.
HELICOBACTER (2020)
The Puzzle of Coccoid Forms ofHelicobacter pylori: Beyond Basic Science
Enzo Ierardi et al.
ANTIBIOTICS-BASEL (2020)
Clinical impact of vonoprazan-based dual therapy with amoxicillin forH. pyloriinfection in a treatment-naive cohort of junior high school students in Japan
Takuji Gotoda et al.
JOURNAL OF GASTROENTEROLOGY (2020)
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-lineHelicobacter pyloriinfection eradication: A randomized trial
Zhiqiang Song et al.
HELICOBACTER (2020)
High dose PPI-amoxicillin dual therapy for the treatment ofHelicobacter pyloriinfection: a systematic review with meta-analysis
Yang-Jie Zhu et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial
Wei-Chen Tai et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults
Cong He et al.
HELICOBACTER (2019)
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
Jyh-Ming Liou et al.
LANCET INFECTIOUS DISEASES (2019)
Evaluation and Management of Penicillin Allergy A Review
Erica S. Shenoy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
Jing Yang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
EFFICACY OF HIGH-DOSE DUAL THERAPY VERSUS BISMUTH-CONTAINING QUADRUPLE THERAPY FOR FIRST-LINE TREATMENT OF HELICOBACTER PYLORI INFECTION AND AN INTERIM REPORT OF MULTI-CENTER, RANDOMIZED CONTROL STUDY
Chi-Tan Hu et al.
GASTROENTEROLOGY (2017)
The Human Gastric Microbiome Is Predicated upon Infection with Helicobacter pylori
Ingeborg Klymiuk et al.
FRONTIERS IN MICROBIOLOGY (2017)
Optimized high-dose amoxicillinuproton-pump inhibitor dual therapies fail to achieve high cure rates in China
Jia-Li Hu et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2017)
A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori
Ferdane Sapmaz et al.
AMERICAN JOURNAL OF THERAPEUTICS (2017)
Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
Y. Sakurai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
Jyh-Chin Yang et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea
Seung Young Kim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Dual therapy for third-lineHelicobacter pylorieradication and urea breath test prediction
Toshihiro Nishizawa
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection
Hyun Kyung Park et al.
CLINICAL ENDOSCOPY (2011)
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy
Naohito Shirai et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin
S. Miehlke et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Molecular analysis of the bacterial microbiota in the human stomach
EM Bik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin
S Miehlke et al.
HELICOBACTER (2003)
分享论文
